Fig. 3From: Comparison of treatment effect sizes from pivotal and postapproval trials of novel therapeutics approved by the FDA based on surrogate markers of disease: a meta-epidemiological studyRatios of odds ratios comparing pivotal and postapproval trials fulfilling at least two matching criteria and reporting non-continuous endpointsBack to article page